Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bellary, S.
Right arrow Articles by Barnett, A. H
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Inhaled insulin: overcoming barriers to insulin therapy?

Srikanth Bellary

Department of Medicine-Undergraduate Centre, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK

Anthony H Barnett

Department of Medicine-Undergraduate Centre, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK, anthony.barnett{at}heartofengland.nhs.uk

nhaled insulin is a new route of insulin delivery that can be used in the treatment of type 1 and type 2 diabetes. It offers an alternative and additional means of insulin administration, and has been received with particular satisfaction by patients who dislike injections. Trials indicate that inhaled insulin can be used effectively for pre-meal bolus intensification of treatment. Pre-meal inhaled insulin with Exubera® has shown faster absorption and similar duration of action to regular subcutaneous insulin with an overall similar glucodynamic effect. Although bioavailability is lower, mainly due to losses in the upper airways, this is compensated for by dose. The commonest side effect reported with inhaled insulin, as with subcutaneous insulin, was hypoglycaemia, almost a quarter of patients noted a cough which settled with continued treatment. Increased antibody titres and changes in lung function return to normal on discontinuation of inhaled insulin. Quality of life scores indicate patient preference for inhaled versus injected insulin, thus increased choice may improve adherence to treatment regimens. However, true cost:benefit analyses have to be undertaken as do studies in children, smokers and people with respiratory conditions, e.g. asthma.

Key Words: Exubera® • inhaled insulin • diabetes.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3, 103-108 (2006)
DOI: 10.1177/14746514060060030201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
C. J Bailey and A. H Barnett
Why is Exubera being withdrawn?
BMJ, December 1, 2007; 335(7630): 1156 - 1156.
[Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
C. J Bailey, C. Day, and A. H Barnett
Exubera expires
The British Journal of Diabetes & Vascular Disease, November 1, 2007; 7(6): 255 - 256.
[PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
S. Bellary and A. H Barnett
Inhaled insulin (Exubera(R)): combining efficacy and convenience
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 179 - 185.
[Abstract] [PDF]